Bank of New York Mellon
CYT

Bank of New York Mellon’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Bank of New York Mellon’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,005
Closed -$94K – 4728
2022
Q1 		$94K Buy
25,005
+7,855
+46% +$44.7K ﹤0.01% 4416
2021
Q4 		$195K Buy
17,150
+1,499
+10% +$22.8K ﹤0.01% 4281
2021
Q3 		$275K Buy
+15,651
New +$293K ﹤0.01% 4077

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon's CYT Position: Q2 2022 in Review

Bank of New York Mellon sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 25,005 shares — an estimated $94K sold.

Bank of New York Mellon first reported a position in CYT in Q3 2021 and held it in 3 quarters. The position peaked at $275K in Q3 2021. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • Bank of New York Mellon reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 25,005 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $94K.
  • Bank of New York Mellon first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Bank of New York Mellon's Cyteir Therapeutics, Inc. Common Stock position peaked at $275K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.